Evidence map›Paper›PMID 31297438›Full record

ReviewAlzheimer's & dementia (New York, N. Y.)2019

Tackling gaps in developing life-changing treatments for dementia.

Rui Mauricio, Caroline Benn, John Davis, Gerry Dawson, Lee A Dawson, Alison Evans, Nick Fox, John Gallacher, Mike Hutton, John Isaac and 20 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Alzheimer's & dementia (New York, N. Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Immunomodulation in age-related disorders and nanotechnology interventions.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023
    Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Rui MauricioAlzheimer's Research UK, Cambridge, UK.
Caroline BennDementia Discovery Fund, London, UK.
John DavisAlzheimer's Research UK Oxford Drug Discovery Institute, University of Oxford, Oxford, UK.
Gerry DawsonP1 Vital, Howbery Business Park, Wallingford, Oxfordshire, UK.
Lee A DawsonCerevance Ltd, Cambridge Science Park, Cambridge, UK.
Alison EvansAlzheimer's Research UK, Cambridge, UK.
Nick FoxDementia Research Centre, Institute of Neurology, University College London, London, UK.
John GallacherDepartment of Psychiatry, University of Oxford, Oxford, UK.
Mike HuttonEli Lilly and Company Limited, Surrey, UK.
John IsaacNeuroscience External Innovation, Neuroscience Therapeutic Area, Johnson & Johnson Innovation, London, UK.
Declan N C JonesNeuroscience External Innovation, Neuroscience Therapeutic Area, Johnson & Johnson Innovation, London, UK.
Lesley JonesMRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff, Wales, UK.
Giovanna LalliUK Dementia Research Institute, UCL, London, UK.
Vincenzo LibriInstitute of Neurology, University College London, London, UK.
Simon LovestoneDepartment of Psychiatry, University of Oxford, Oxford, UK.
Catherine MoodyMedical Research Council Head Office, London, UK.
Wendy NobleDepartment of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Hugh PerryFaculty of Natural and Environmental Sciences, University of Southampton, Southampton, UK.
James PickettAlzheimer's Society, London, UK.
David ReynoldsAlzheimer's Research UK, Cambridge, UK.
Craig RitchieCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
Jonathan D RohrerDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.
Carol RoutledgeAlzheimer's Research UK, Cambridge, UK.
James RoweDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Heather SnyderAlzheimer's Association, Chicago, IL, USA.
Tara Spires-JonesUK Dementia Research Institute, The University of Edinburgh, Edinburgh, UK.
Jina SwartzEuropean Innovation Hub, Merck Sharp and Dohme, London, UK.
Luc TruyenJanssen Research & Development LLC, Titusville, NJ, USA.
Paul WhitingDementia Research Institute, UCL, London, UK.
Therapeutics for Dementia Consortium

Funding

Medical Research Council MR/L010305/1Medical Research Council MR/L023784/2Medical Research Council MR/M02492X/1
6 · The paper itself

Abstract

Since the G8 dementia summit in 2013, a number of initiatives have been established with the aim of facilitating the discovery of a disease-modifying treatment for dementia by 2025. This report is a summary of the findings and recommendations of a meeting titled "Tackling gaps in developing life-changing treatments for dementia", hosted by Alzheimer's Research UK in May 2018. The aim of the meeting was to identify, review, and highlight the areas in dementia research that are not currently being addressed by existing initiatives. It reflects the views of leading experts in the field of neurodegeneration research challenged with developing a strategic action plan to address these gaps and make recommendations on how to achieve the G8 dementia summit goals. The plan calls for significant advances in (1) translating newly identified genetic risk factors into a better understanding of the impacted biological processes; (2) enhanced understanding of selective neuronal resilience to inform novel drug targets; (3) facilitating robust and reproducible drug-target validation; (4) appropriate and evidence-based selection of appropriate subjects for proof-of-concept clinical trials; (5) improving approaches to assess drug-target engagement in humans; and (6) innovative approaches in conducting clinical trials if we are able to detect disease 10-15 years earlier than we currently do today.

Indexed as

Alzheimer's diseaseClinical trialsDementiaDiagnosisDisease-modifying treatmentEarlier detectionGenetic risk factorsNeurodegenerationTarget validation

Identifiers

PMID31297438
PMCPMC6597931

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.